PT  - JOURNAL ARTICLE
AU  - Atsushi Shimizu
AU  - Tomoyuki Ohe
AU  - Masato Chiba
TI  - A Novel Method for the Determination of the Site of Glucuronidation by Ion Mobility Spectrometry-Mass Spectrometry
AID  - 10.1124/dmd.112.045435
DP  - 2012 Aug 01
TA  - Drug Metabolism and Disposition
PG  - 1456--1459
VI  - 40
IP  - 8
4099  - http://dmd.aspetjournals.org/content/40/8/1456.short
4100  - http://dmd.aspetjournals.org/content/40/8/1456.full
SO  - Drug Metab Dispos2012 Aug 01; 40
AB  - Glucuronidation not only plays a detoxifying role in living body, but it also can complicate pharmacological and toxicological profiles of new drug candidates by forming active and reactive conjugated metabolites. The opportunity to elucidate structure of conjugated metabolites has increased in drug metabolism studies at the early development stage. General methodologies for the structure elucidation of glucuronide conjugate(s) include liquid chromatography-tandem mass spectrometry (LC-MS/MS) and NMR spectroscopy. In many cases, LC-MS/MS alone cannot unequivocally identify the site(s) of conjugation in isomeric glucuronidations. In the present study, we established a new strategy for the structure elucidation of glucuronide conjugates using ion mobility spectrometry (IMS)-mass spectrometry. Linear correlation between calculated collision cross-sections (CCS) and actual drift times from IMS was found for each set of parent compound (raloxifene, losartan, telmisartan, and estradiol) and the corresponding MS/MS product ions. Thus, obtained regression lines accurately and selectively projected the actual drift times of authentic standards of glucuronide conjugate based on the theoretical CCS values. The established method was used for the accurate assignment of predominant formation of phenolic glucuronide conjugate (SCH 60663) in the isomeric (phenolic and benzylic) glucuronidations of ezetimibe in the incubated sample with cryopreserved human hepatocytes. This application demonstrates the potential to facilitate the structure identification of glucuronide conjugates at the early development stage of new drug candidates.